Newsroom-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

ABOUT

About Acepodia

Management Team

Board of Directors

Advisors
TECHNOLOGY

Overview

ACC

γδ2 T Cells

oNK Cells
PIPELINE

ACC-γδ2 T

ACC-oNK
NEWSROOM

All News

Press Releases

Events & Presentations

Publications

Media
PARTNERSHIPS
CONTACT

Contact Us

Careers

Powerful, accessible cell therapies for patients with cancer.

We develop innovative, highly effective cell therapies for cancer that are broadly accessible for patients.

FIND US

Acepodia USA

1600 Harbor Bay Parkway, Suite 140,
Alameda, CA 94502,
USA

Acepodia Taiwan

17F.-7, No. 99, Sec. 1, Xintai 5th Rd.,
Xizhi Dist., New Taipei City 22175,
Taiwan (R.O.C.).

Tel: +1 (415) 366 7822 Email: info@acepodiabio.com

Press Releases
Events & Presentations
Publications
Media
All News

September 172020

ACE1702: A potent and off-the-shelf oNK cell therapy product

Cancer Research, 2020, 80:2169
Hao-Kang H. Li, Tai-Sheng E. Wu, Ching-Wen S. Hsiao, Sen-Han S. Yang, Chia-Yun S. Lee, Yan-Liang J. Lin, Zih-Fei Z. Cheng, Yu-Bei Cheng, Yan-Da D. Lai, Hsiu-Ping C. Yang, Sai-Wen S. Tang, Wei-Lun S. Lo, Janet Pan and Shih-Chia S. Hsiao

Learn more
September 142020

From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer with next-gen cell therapies

Fierce Biotech

Learn more
September 102020

LifeSci Partners Summer Symposium

We recently presented at the LifeSci Partners Summer Symposium. Listen to the full presentation to learn more about our approach, pipeline and the potential of our cell therapy technology to treat various types of cancer.

Learn more
September 042020

Up and down the ladder: The latest comings and goings

STAT News

Learn more
September 012020

Acepodia Strengthens Management Team with Appointments of Biotech Industry Veterans

GlobeNewswire

Learn more
August 252020

Acepodia’s NK Cell Therapy Enters Human Studies in HER2 Expressing Solid Tumors

Precision Oncology News

Learn more
August 252020

Immunotherapy Developer Acepodia Hopes to Slash Cell Therapy Manufacturing Costs

GEN—Genetic Engineering and Biotechnology News

Learn more
August 182020

Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors

GlobeNewswire

Learn more
July 142020

Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies

GlobeNewswire

Learn more
July 012020

In Conversation: Novel Off-The-Shelf Targeted Cell Therapies

Pharma’s Almanac—Nice Insight’s Content Community

Learn more
July 122020

A New Cost Paradigm For CAR Cell Therapies

BioProcess Online

Learn more
June 112020

Innovative Platform Enhancing Immune Cells with Antibodies for Treating Cancer with Sonny Hsiao Acepodia

Empowered Patient Radio Podcast

Learn more

1 2 3 4 5

ACE1702: A potent and off-the-shelf oNK cell therapy product

From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer with next-gen cell therapies

LifeSci Partners Summer Symposium

Up and down the ladder: The latest comings and goings

Acepodia Strengthens Management Team with Appointments of Biotech Industry Veterans

Acepodia’s NK Cell Therapy Enters Human Studies in HER2 Expressing Solid Tumors

Immunotherapy Developer Acepodia Hopes to Slash Cell Therapy Manufacturing Costs

Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors

Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies

In Conversation: Novel Off-The-Shelf Targeted Cell Therapies

A New Cost Paradigm For CAR Cell Therapies

Innovative Platform Enhancing Immune Cells with Antibodies for Treating Cancer with Sonny Hsiao Acepodia